Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
You may also be interested in...
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets.